Logo image of NYXH

NYXOAH SA (NYXH) Stock Fundamental Analysis

NASDAQ:NYXH - Nasdaq - BE0974358906 - Common Stock - Currency: USD

6.035  +0.02 (+0.25%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to NYXH. NYXH was compared to 190 industry peers in the Health Care Equipment & Supplies industry. NYXH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, NYXH is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NYXH has reported negative net income.
NYXH had a negative operating cash flow in the past year.
NYXH had negative earnings in each of the past 5 years.
NYXH had a negative operating cash flow in each of the past 5 years.
NYXH Yearly Net Income VS EBIT VS OCF VS FCFNYXH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

NYXH has a worse Return On Assets (-37.11%) than 61.58% of its industry peers.
NYXH has a Return On Equity (-50.60%) which is in line with its industry peers.
Industry RankSector Rank
ROA -37.11%
ROE -50.6%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NYXH Yearly ROA, ROE, ROICNYXH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

With a decent Gross Margin value of 61.75%, NYXH is doing good in the industry, outperforming 62.11% of the companies in the same industry.
NYXH's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for NYXH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.63%
GM growth 5YN/A
NYXH Yearly Profit, Operating, Gross MarginsNYXH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

4

2. Health

2.1 Basic Checks

NYXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for NYXH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NYXH Yearly Shares OutstandingNYXH Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
NYXH Yearly Total Debt VS Total AssetsNYXH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

NYXH has an Altman-Z score of 0.67. This is a bad value and indicates that NYXH is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.67, NYXH is in line with its industry, outperforming 50.53% of the companies in the same industry.
A Debt/Equity ratio of 0.21 indicates that NYXH is not too dependend on debt financing.
NYXH has a Debt to Equity ratio (0.21) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z 0.67
ROIC/WACCN/A
WACC7.28%
NYXH Yearly LT Debt VS Equity VS FCFNYXH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

A Current Ratio of 5.28 indicates that NYXH has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.28, NYXH is in the better half of the industry, outperforming 77.89% of the companies in the same industry.
NYXH has a Quick Ratio of 4.95. This indicates that NYXH is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of NYXH (4.95) is better than 81.05% of its industry peers.
Industry RankSector Rank
Current Ratio 5.28
Quick Ratio 4.95
NYXH Yearly Current Assets VS Current LiabilitesNYXH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 50M 100M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for NYXH have decreased strongly by -16.03% in the last year.
Looking at the last year, NYXH shows a small growth in Revenue. The Revenue has grown by 3.98% in the last year.
NYXH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 74.42% yearly.
EPS 1Y (TTM)-16.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.84%
Revenue 1Y (TTM)3.98%
Revenue growth 3Y74.42%
Revenue growth 5YN/A
Sales Q2Q%-30.76%

3.2 Future

The Earnings Per Share is expected to grow by 10.70% on average over the next years. This is quite good.
Based on estimates for the next years, NYXH will show a very strong growth in Revenue. The Revenue will grow by 135.57% on average per year.
EPS Next Y-4.2%
EPS Next 2Y5.27%
EPS Next 3Y10.7%
EPS Next 5YN/A
Revenue Next Year411.04%
Revenue Next 2Y257.09%
Revenue Next 3Y224.21%
Revenue Next 5Y135.57%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NYXH Yearly Revenue VS EstimatesNYXH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
NYXH Yearly EPS VS EstimatesNYXH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NYXH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NYXH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NYXH Price Earnings VS Forward Price EarningsNYXH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NYXH Per share dataNYXH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.27%
EPS Next 3Y10.7%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NYXH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NYXOAH SA

NASDAQ:NYXH (4/17/2025, 8:00:02 PM)

6.035

+0.02 (+0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-13 2025-03-13/bmo
Earnings (Next)05-13 2025-05-13
Inst Owners32.66%
Inst Owner Change0%
Ins Owners20.26%
Ins Owner ChangeN/A
Market Cap225.89M
Analysts81.43
Price Target15.76 (161.14%)
Short Float %0.43%
Short Ratio2.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.42%
Min EPS beat(2)-3.56%
Max EPS beat(2)0.72%
EPS beat(4)3
Avg EPS beat(4)0.17%
Min EPS beat(4)-3.56%
Max EPS beat(4)2.33%
EPS beat(8)4
Avg EPS beat(8)-11.67%
EPS beat(12)7
Avg EPS beat(12)-3.29%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-33%
Min Revenue beat(2)-55.92%
Max Revenue beat(2)-10.09%
Revenue beat(4)1
Avg Revenue beat(4)-17.48%
Min Revenue beat(4)-55.92%
Max Revenue beat(4)4.47%
Revenue beat(8)1
Avg Revenue beat(8)-28.22%
Revenue beat(12)1
Avg Revenue beat(12)-36.62%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.68%
PT rev (3m)10.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-6.41%
EPS NY rev (3m)-7.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 39.13
P/FCF N/A
P/OCF N/A
P/B 1.9
P/tB 3.61
EV/EBITDA N/A
EPS(TTM)-2.05
EYN/A
EPS(NY)-2.13
Fwd EYN/A
FCF(TTM)-1.51
FCFYN/A
OCF(TTM)-1.48
OCFYN/A
SpS0.15
BVpS3.18
TBVpS1.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.11%
ROE -50.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.75%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.63%
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.42%
Cap/Sales 18.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.28
Quick Ratio 4.95
Altman-Z 0.67
F-Score3
WACC7.28%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.84%
EPS Next Y-4.2%
EPS Next 2Y5.27%
EPS Next 3Y10.7%
EPS Next 5YN/A
Revenue 1Y (TTM)3.98%
Revenue growth 3Y74.42%
Revenue growth 5YN/A
Sales Q2Q%-30.76%
Revenue Next Year411.04%
Revenue Next 2Y257.09%
Revenue Next 3Y224.21%
Revenue Next 5Y135.57%
EBIT growth 1Y-18.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.18%
EBIT Next 3Y4.2%
EBIT Next 5Y11.04%
FCF growth 1Y-7.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.06%
OCF growth 3YN/A
OCF growth 5YN/A